A Study To Develop A Biorepository Of Blood Samples From Cancer Patients Participating In The Gemini (IRB 19-006717) Protocol
Overview
Tab Title Description
Study type
ObservationalDescribes the nature of a clinical study. Types include:
- Observational study — observes people and measures outcomes without affecting results.
- Interventional study (clinical trial) — studies new tests, treatments, drugs, surgical procedures or devices.
- Medical records research — uses historical information collected from medical records of large groups of people to study how diseases progress and which treatments and surgeries work best.
Study IDs
Site IRB
- Scottsdale/Phoenix, Arizona: 19-009560
- Jacksonville, Florida: 19-009560
Sponsor Protocol Number: 19-009560
About this study
The purpose of this study is to develop a biorepository of blood samples from cancer patients participating in the Gemini (IRB 19-006717) protocol. These samples will be used for future biomarker discovery and other translational studies.
Participation eligibility
Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.
Inclusion Criteria:
- Patients at least 18 years of age.
- Individuals diagnosed with any solid tumor cancer including, but not limited to, gastrointestinal, breast, gynecological, genitourinary, skin, CNS/brain, head/neck, musculoskeletal or cancer of unknown primary; and presenting to Mayo Clinic for clinical management/treatment; and patients receive genetic testing as described above.
- Self-identified as being from various ethnic populations including Hispanic/Latino, Native American/Alaskan, African American (including of African descent),Asian and other European populations.
- Blood collection is feasible (health, access and/or tolerability) for requested blood sample(s).
- Individuals have agreed to participate and signed the study informed consent form.
Exclusion Criteria:
- Patients who have had prior germline genetic testing involving a 40+ gene panel within the last 24 months at Mayo Clinic and available for review by the research coordinator at time of consent.
Participating Mayo Clinic locations
Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.
| Mayo Clinic Location |
Status |
Contact |
Scottsdale/Phoenix, Ariz.
Mayo Clinic principal investigator Niloy Jewel Samadder, M.D. |
Open for enrollment |
Contact information:
Cancer Center Clinical Trials Referral Office
(855) 776-0015
|
Jacksonville, Fla.
Mayo Clinic principal investigator Jeremy Jones, M.D. |
Open for enrollment |
|
More information
Publications
Publications are currently not available